Immunotherapy combined with antiangiogenic agents in patients with advanced malignant pleural mesothelioma: A case report.

ABSTRACT:

Background

Malignant pleural mesothelioma has limited therapeutic options and a poor outcome. Antiangiogenic agents might increase the efficacy of immunotherapy as second-line treatment of advanced-stage malignancies.

Case summary

A patient with stage IIIB pleural mesothelioma received second-line treatment with a combination of pembrolizumab, bevacizumab and chemotherapy following standard chemotherapy under the guidance of second-generation sequencing. He achieved a partial response after four cycles of treatment with progression-free survival of 5 mo. Pembrolizumab was suspended due to grade 2 immunerelated pneumonia, which was resolved by oral glucocorticoids. However, disease progression was observed after immunotherapy rechallenge and anlotinib therapy. The patient had

SUBMITTER: Xuan TT 

PROVIDER: S-EPMC9403696 | biostudies-literature | 2022 Aug

REPOSITORIES: biostudies-literature